Strain Report - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Strain: SHRSP/A3NCrl

Symbol: SHRSP/A3NCrl
Strain: SHRSP
Substrain: A3NCrl
Full Name: Stroke Prone Rats
RGD ID: 2311051
RRID: RGD_2311051
Ontology ID: RS:0002538
Type: inbred
Source: Charles River Laboratories
Origin: The Spontaneously Hypertensive Stroke Prone Rat (SHRSP) was isolated from Wistar-Kyoto rats by Okamoto and Aoki in 1963. The A3 subline was transferred to the National Institutes of Health in 1975 from Yamori at generation F36. To Charles River in 2002.
Coat Color: Albino
Last Known Status: Unknown





Disease Annotations     Click to see Annotation Detail View


Phenotype Values via PhenoMiner     Click to see Annotation Detail View
Options:  View chart  |  Download data table  |  View expanded data table

Clinical Measurement
systolic blood pressure
mean arterial blood pressure
body weight
blood urea nitrogen level
ejection fraction
end-systolic volume
cardiac output
end-diastolic volume
stroke volume
timed urine volume
heart left ventricle weight to body weight ratio
concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50)
concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50)
sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel
urine albumin excretion rate
urine sodium excretion rate
creatinine clearance
brain infarction volume
percentage of study population displaying hematuria at a point in time
ratio of survivors in a study population during a period of time
concentration of carbachol at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50)
carbachol-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel
BAY 60-4552-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel
concentration of BAY 60-4552 at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50)
GSK2181236A-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel
concentration of GSK2181236A at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50)
time to peak measurement of Gd-DTPA uptake by kidney cortex
percentage of study population displaying glycosuria at a point in time
percentage of study population developing cerebral beta-amyloid deposits during a period of time
percentage of study population developing cerebral small perivascular bleeds during a period of time
percentage of study population developing cerebral small vessel thrombosis and adjacent tissue infarction during a period of time
percentage of study population developing cerebral small perivascular bleeds and beta-amyloid deposits during a period of time
percentage of study population developing cerebral small perivascular bleeds and no beta-amyloid deposits during a period of time
percentage of study population developing renal vascular pathology during a period of time
partial pressure of brain white matter oxygen
multiregional glomerular filtration rate index
percentage of study population developing kidney tubulointerstitial damage during a period of time
phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride

References


Region

Damaging Variants
Number of Damaging Variants
SampleRnor_6.0Rnor_5.0RGSC_v3.4
SHRSP/A3NCrl (2019) 2896
SHRSP/A3NCrl (2019)


Additional Information